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Abstract
Background: There is no consensus on the preferred method for defining the non-inferiority margin in non-inferiority
trials, and previous studies showed that the rationale for its choice is often not reported. This study investigated how
the non-inferiority margin is defined in the published literature, and whether its reporting has changed over time.
Methods: A systematic PubMed search was conducted for all published randomized, double-blind, non-inferiority trials
from January 1, 1966, to February 6, 2015. The primary outcome was the number of margins that were defined by
methods other than the historical evidence of the active comparator. This was evaluated for a time trend. We also
assessed the under-reporting of the methods of defining the margin as a secondary outcome, and whether this
changed over time. Both outcomes were analyzed using a Poisson log-linear model. Predictors for better reporting of
the methods, and the use of the fixed-margin method (one of the historical evidence methods) were also analyzed
using logistic regression.
Results: Two hundred seventy-three articles were included, which account for 273 non-inferiority margins. There was
no statistically significant difference in the number of margins that were defined by other methods compared to those
defined based on the historical evidence (ratio 2.17, 95% CI 0.86 to 5.82, p = 0.11), and this did not change over time.
The number of margins for which methods were unreported was similar to those with reported methods (ratio 1.35,
95% CI 0.76 to 2.43, p = 0.31), with no change over time. The method of defining the margin was less often reported in
journals with low-impact factors compared to journals with high-impact factors (OR 0.20; 95% CI 0.10 to 0.37,
p < 0.0001). The publication of the FDA draft guidance in 2010 was associated with increased reporting of the
fixed-margin method (after versus before 2010) (OR 3.54; 95% CI 1.12 to 13.35, p = 0.04).
Conclusions: Non-inferiority margins are not commonly defined based on the historical evidence of the active
comparator, and they are poorly reported. Authors, reviewers, and editors need to take notice of reporting this
critical information to allow for better judgment of non-inferiority trials.
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Background
Non-inferiority trials are a relatively new design of ran-
domized clinical trials, which are increasingly being pub-
lished [1]. Non-inferiority trials are conducted to
investigate whether the efficacy of a novel (test) drug is
not worse than that of an active comparator according
to a predefined non-inferiority margin [2–4].
There is no consensus on the preferred method for de-
fining the non-inferiority margin. Regulatory guidelines
recommend defining the margin based on a comprehen-
sive review of the historical evidence of the efficacy of
the active comparator (mainly against placebo) [2, 5–7].
Only the US Food and Drug Administration (FDA) draft
guideline recommends explicit methods on how to define
the margin based on clinical and statistical considerations
[2]. Other regulatory guidelines provide more general rec-
ommendations [5–7]. The impact of these guidelines in
general, and the FDA draft guideline in particular, on the
choice of non-inferiority margin is unknown. Most of the
previous reviews on the methodological quality of pub-
lished non-inferiority trials did not provide data on
whether, and how, the historical evidence of the active
comparator was used to define the margin [8–12].
The extension of the Consolidated Standards of
Reporting Trials (CONSORT) Statement for reporting
non-inferiority and equivalence randomized trials was
published in 2006 to improve the quality of reporting
non-inferiority and equivalence trials [13, 14]. This ex-
tension recommends that the margin and how it relates
to the effect of the active comparator in any placebo-
controlled trial should be noted. Three systematic re-
views on non-inferiority trials found no significant impact
of this statement on reporting the rationale for the choice
of the margin in a before-after comparison [9, 10, 12].
None of these reviews provide details about the endorse-
ment of the CONSORT Statement, and whether the
reporting of the rationale for the choice of the margin was
different in CONSORT-endorsing journals versus non-
CONSORT-endorsing journals.
The aim of this systematic review was to identify the
methods that are being used to define the non-inferiority
margin in the published non-inferiority trials, and whether
the margin is defined based on methods other than the
historical evidence of the active comparator.
Methods
Study selection and search strategy
A systematic PubMed search was conducted for all pub-
lished randomized, double-blind, non-inferiority trials. The
search included the period January 1, 1966, to February 6,
2015, using (Noninferiority [Title/Abstract] AND double-
blind study [MeSH Terms]) as search items, and it was
restricted to randomized controlled trial, humans, and
English-language publications. We targeted non-inferiority
trials that could potentially have had an impact on drug
regulatory decisions. Therefore, we excluded the fol-
lowing studies: phase I studies, pharmacodynamic
studies, pharmacokinetic studies, bioequivalence stud-
ies, open-label and single-blind studies, studies with a
non-pharmacological intervention as the experimental
treatment, subgroup analysis, post hoc analysis, secondary
analysis, extension studies of previously published studies,
and published protocols.
Methods of defining the non-inferiority margin
The non-inferiority margin is used to assess whether the
test drug will preserve what is considered a clinically sig-
nificant fraction of the effect of the active comparator.
To that aim, historical evidence on the active comparator
from (a meta-analysis of) placebo-controlled (and/or ac-
tive controlled trials) is used [2, 15–17]. The point-
estimate and the fixed-margin methods are methods of
analyzing non-inferiority where the margin is defined
based either on the effect estimate from the historical evi-
dence or the limit of the confidence interval of the effect
estimate that is the closest to the null effect. In the point-
estimate method, the fraction of the effect estimate that is
considered clinically significant is determined based on
clinical judgement [15]. This fraction is then called the
preserved fraction. The margin represents the remaining
fraction of the point estimate of the active comparator
that stakeholders are willing to lose at a cost of gaining
other advantages that are claimed to be offered by the
test drug (such as advantages in terms of safety or ad-
ministration) [2, 15–18].
In the point-estimate method, the margin is defined
based on the effect estimate, which does not capture the
variance of the effect estimates of the active comparator
from the past trials, and may not reflect the placebo-
controlled effect of the active comparator that is expected
to be present in the non-inferiority trial if a placebo arm
were included [2, 15, 16]. This may lead to an estimation
of a margin that is either too lenient or too strict. On
the other hand, the fixed-margin method, the method
that is recommended by the FDA, takes this into ac-
count by defining the margin based on the smallest ef-
fect size of the active comparator from the past trials
(as expressed by the confidence limit that is closest to
the null effect) [2, 15, 16].
The margin that was defined based on the pooled ef-
fect estimate in the point-estimate method can be
used in another method of analysis of non-inferiority
trials which is called the synthesis method. The differ-
ence between the point-estimate method and the syn-
thesis method is that in the latter the variance of the
effect estimates of the active comparator is incorpo-
rated in the analysis of non-inferiority (not in setting
the margin) [2, 15, 16].
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For this review, if the margin was not defined accord-
ing to one of the aforementioned methods, the method
that was used to define the margin was classified as
“other methods”. A further subclassification of other
methods was provided based on the type of general justi-
fication that was stated in each article for defining the
margin. The method was considered “not reported”
when the method of defining the margin was not stated
in the article.
Data extraction and assessment
The search in PubMed and the screening of each title
and abstract was conducted by TA to identify eligible
studies. Based on the full texts of eligible studies, the fol-
lowing were extracted from each article: (1) report char-
acteristics: authors, the published journal, the date of
publication, the number of trials in each article, the test
and the active comparator, the indication, and the chosen
outcome for analyzing non-inferiority; (2) information
about the margin: the predefined non-inferiority mar-
gin(s), the choice and motivation of the margin, and the
preserved fraction. A random sample of 10% of the total
number of the included articles was also reviewed by AdB,
OK, and RG to assess interobserver reliability. Disagree-
ment occurred in one article with regard to the type of the
method that was used to define the margin (kappa = 0.95).
When available, the online supplementary materials of
each article were checked. Additionally, the cited refer-
ences were checked when the description of the choice of
the margin was not clear. Discussions to reach consensus
were held among the research team members to give a
final classification of the method when the description of
the choice of the margin was not clear in the original full
text.
The endorsement of the CONSORT Statement was
checked in the “Instructions for Authors” section in each
journal. When reporting non-inferiority trials, the original
CONSORT Statement recommends reading the extension
of the CONSORT Statement for non-inferiority and
equivalence trials [13, 14, 19]. A journal was classified as a
CONSORT-endorsing journal if it endorses either the
CONSORT Statement or the International Committee of
Medical Journal Editors’ (ICMJE) uniform requirements
for manuscripts submitted to biomedical journals [20].
We classified the journals into high- or low-impact jour-
nals based on the impact factor of each journal in the year
of publishing the non-inferiority trial. The impact factor
of each journal was collected from InCites™ Journal Cit-
ation Reports® (JCR) [21]. Journals with an impact factor
of ten or more were classified as high-impact journals. For
journals that do not have impact factors in the year of
publication of the non-inferiority trial, the classification
was based on the impact factor of the preceding or the
succeeding year depending on the availability of the
impact factor. The impact factors of two journals,
SKINmed Dermatology for the Clinician and Infectious
Diseases in Obstetrics and Gynecology, were not provided
neither by JCR nor by their original websites. Thus they
were considered as low-impact journals.
The impact of the FDA draft guidance on the use of
the fixed-margin method, the recommended method by
the FDA, was checked before and after the publication
of this guidance in 2010 (articles that were published in
and before 2010 compared to those published in 2011
and thereafter). The FDA draft guideline was chosen be-
cause it is the last published regulatory guideline, and it
is the only one that provides explicit methods to define
the margin. The adherence with the CONSORT State-
ment in reporting the rationale for the choice of the
margin was analyzed in articles that were published in
and before 2006 compared to those published in 2007
and thereafter. The reporting of the rationale was also
analyzed in CONSORT-endorsing versus non-CONSORT-
endorsing journals, and in high- versus low-impact
journals.
Study outcomes
The primary outcome of the study was the number of
margins that were defined by “other methods”. This
number was compared to the number of margins that
were defined by the historical evidence of the active
comparator (ratio), and was assessed for a time trend.
The secondary outcome was the number of margins
with unreported methods, which was compared to the
number of margins with reported methods (regardless of
the method type), and evaluated for a time trend. The
odds of not reporting the method of defining the margin
(margins with unreported methods/margins with reported
method) were assessed for three predictors: the publica-
tion of the extension of the CONSORT Statement in 2006
(before versus after), the endorsement of the CONSORT
Statement by the journals (endorsing versus non-
endorsing), and the journals’ impact factor (high versus
low). Finally, the odds of using the fixed-margin method
to define the margin were assessed before versus after the
publication of the 2010 FDA draft guidance.
The analyses were conducted based on the margin that
was used to analyze the primary outcome in each trial
(i.e., one margin per trial). If more than one margin was
used in a trial, and it was not clear which margin was for
the primary analysis, the one that was used for the sample
size calculation was used. If both margins were used in
the sample size calculation, the margin that was stated
first was used. Even if the analysis of non-inferiority was a
secondary outcome in a trial (i.e., superiority was the pri-
mary outcome), it was considered in this review. A sensi-
tivity analysis was performed for all outcomes using all
margins that were used in the included trials.
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Statistical analysis
A descriptive statistical summary was provided for the
methods used to define the margin and for the preserved
fractions. Poisson regression was used to test whether
the number of margins that were defined based on other
methods was different compared to the number of those
defined based on the historical evidence of the active
comparator, and whether the ratio of these numbers has
changed over the years (the margins with unreported
methods were excluded from this model). The change
was determined by assessing the interaction between
method and the year of publication. A separate Poisson
model was also used to estimate the ratio of number of
margins with unreported methods to the number of
margins with reported methods (margins defined based
on the historical evidence and other methods). The year
of publication was added as an independent variable and
the interaction with the method variable was assessed to
determine whether the ratio changed over the years. The
odds of not reporting the method for the three predic-
tors, and the impact of the FDA draft guidance on the
odds of using the fixed-margin method were assessed
using logistic regression.
A sensitivity analysis was performed using all margins
that were identified in the included articles. A propor-
tion of the included trials used more than one non-
inferiority margin to analyze non-inferiority for one or
more outcomes. The sensitivity analysis was conducted
for the primary outcome using a Poisson model using all
margins with reported methods. Nevertheless, the effect
of clustering was ignored. Similarly, the clustering was
ignored in the sensitivity analysis of the secondary out-
come that was conducted using all identified margins.
The sensitivity analyses of the three predictors and the
use of the fixed-margin method using all reported mar-
gins were conducted using the generalized estimating
equations with a logit link and an exchangeable correl-
ation matrix. All statistical analyses were performed
using IBM® SPSS® Statistics for Windows Version 23.0
(IBM Corp., Armonk, NY, USA). This review was re-
ported according to PRISMA (Additional file 1: PRISMA
checklist).
Results
Identification of articles in the systematic review
The PubMed search yielded 350 abstracts. After screen-
ing these abstracts using our inclusion and exclusion cri-
teria, the full texts of 288 articles were retrieved and
assessed for eligibility. The selection and exclusion pro-
cesses are illustrated in a PRISMA flow diagram (Fig. 1).
The screened articles were published in the period from
2000 to 2015. A bibliography of the finally included arti-
cles in this review is provided as a supplementary mater-
ial. We finally included 273 articles that account for 273
primary non-inferiority margins. Some articles reported
a pooled non-inferiority analysis for two or more trials
(we considered them as one trial). Thirty-seven trials
(13.5%) used two or more margins to assess non-
inferiority for one or more outcomes; the total number
of margins identified was 326.
Primary and secondary outcomes
Information about how the margin was defined was
available for only 115 of 273 margins (42.1%). Among
these 115 margins, the historical evidence of the active
comparator was used to define 47 margins (40.1%), and
68 (59.9%) were defined by other methods (Table 1). The
ratio of the number of margins that were defined by the
other methods compared to the number of margins that
were defined by historical evidence of the active com-
parator (ratio 2.17, 95% CI 0.86 to 5.82, p = 0.11) did not
change over the years (i.e., no significant interaction be-
tween the method and the year variables) (Fig. 2). The
preserved fractions that were used in the historical evi-
dence methods ranged from 0 to 85% (Fig. 3).
The method was not reported for 158 of 273 margins
(57.9%). The ratio of the number of margins with unre-
ported methods (n = 158) compared to the number of
margins with reported methods (n = 115) (ratio 1.35,
95% CI 0.76 to 2.43, p = 0.31) did not change over time
(i.e., no significant interaction between the reporting of
the method and the year variables) (Fig. 4).
The results of the sensitivity analysis for the primary,
secondary, and other outcomes were consistent with the
results of the original analyses (supplementary materials).
Fig. 1 Flow chart of the search and screening process
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Predictors for reporting the methods of defining the
non-inferiority margin
The odds of not reporting the method of defining the
margin after versus before the publication of the 2006
extension of the CONSORT Statement were comparable
(OR 1.08; 95% CI 0.61 to 1.91, p = 0.80). Also, the 214
(78.4%) margins reported in CONSORT-endorsing jour-
nals and the 59 (21.6%) margins reported in non-
CONSORT-endorsing journals did not differ regarding
the under-reporting of the method (OR 0.77; 95% CI
0.42 to 1.39, p = 0.4). However, the method for defining
the margin was less often reported in low-impact jour-
nals in comparison to high-impact journals (OR 0.20;
95% CI 0.10 to 0.37, p < 0.0001).
The impact of the FDA draft guidance on the use of the
fixed-margin method
Thirty-four of 273 margins were defined based on the
historical evidence of the active comparator using the ef-
fect estimate (33 were used to analyze non-inferiority by
the point-estimate method, and one by the synthesis
method). Thirteen margins of 273 (4.8%) were defined
based on the limit of the confidence interval that is the
closest to the null effect (the fixed-margin method). The
publication of the FDA draft guidance in 2010 was asso-
ciated with increased reporting of the fixed-margin
method (after versus before 2010) (OR 3.54; 95% CI 1.12
to 13.35, p = 0.04). The use of this method increased
from 4/163 (2.5%) before to 9/110 (8.2%) after the publi-
cation of the guidance.
Discussion
We have not found a trend of an increase in the use of
the historical evidence to define the non-inferiority mar-
gin compared to other methods. Even though the num-
ber of margins that were defined by the fixed-margin
method increased after the publication of the FDA draft
guidance, the proportion of these margins is very small.
We also observed that the rationale for the choice of the
non-inferiority margin is often not reported without a
trend of improvement. As for predictors, only the publi-
cation in high-impact journals was associated with a bet-
ter reporting of the methods of defining the margin.
Table 1 Classification of other methods used to define the margins in the systematic review
Subtype Definition Frequency
(n = 68)
Expert opinion The non-inferiority margin was chosen based on expert opinion. It also includes
defining the margin based on: (1) the Delphi approach, (2) a threshold (e.g., superiority
margin) for clinical efficacy that was chosen from the literature and considered by the
authors, researchers, or experts as a clinically acceptable non-inferiority margin
42 (62%)
Based on literature review 1. Non-specific literature review: the choice of the margin was based on a review of
the literature without indicating how the review was conducted, and what types of
historical data were reviewed
3 (5%)
2. Based on historically controlled data: the margin was defined based on the
assessment of historical experience from non-concurrently controlled trials. The
relative efficacy of the historical experience of active comparator was assessed
against a historical group (e.g., placebo group, spontaneous cure rate group, or
outcome without treatment group)
2 (3%)
3. Review of other types of literature: the margin was defined based on the
assessment of other types of literature (e.g., observational studies)
2 (3%)
The margin was used in other non-inferiority
trial(s) with similar design
A similar margin was used in other non-inferiority trial(s) of drugs that are used to
treat the same indication, regardless of whether the active comparator was used in
these trials or not
9 (13%)
Regulatory consultation/guideline The choice of the margin was based on one of the following: recommendations by a
regulatory authority, following a guideline from a regulatory authority without indicating
how the margin was exactly defined, or used a margin that is provided by one of the
regulatory guidelines without indicating how exactly it was defined (neither by the
authors nor by the guideline)
5 (7%)
Based on the efficacy of the experimental
drug from the previous clinical trials
The margin was defined based on the efficacy of the experimental drug itself from
the previous trials
5 (7%)
Fig. 2 The number of margins defined by other methods versus the
historical evidence over time
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The proportion of the margins in this systematic re-
view that were defined based on historical evidence
(17.2% of 273 trials) was larger than the proportion that
was found by Lange and Freitag (8% of 314 trials) [19].
The latter review was the only review that provided de-
tails on how the data of the active comparator were
exactly used to define the margin. Most of the other
reviews reported whether the margin was defined based
on “clinical or statistical considerations”, or whether it
was defined based on “clinical and statistical consider-
ations or results of a previous study” [8–11]. We found a
wide range of preserved fractions used (0 to 85%), with a
median of 50%. This median preserved fraction is in be-
tween the median preserved fractions found by Lange
and Freitag (less than 50%) and by Wangge et al. (greater
than 50%) [9, 22].
The rationale for the choice of the non-inferiority mar-
gin was not provided for more than half of the margins
in this systematic review. This is consistent with the
range of under-reporting of the rationale in previous re-
views (54.3 to 84.7%) [8–12, 22, 23]. Our results are also
comparable to the results of previous systematic reviews
with regard to the insignificant impact of the extension
of the CONSORT Statement on the reporting of the ra-
tionale for the choice of the margin so far. Additionally,
we found no difference in reporting the rationale
Fig. 3 The range of preserved fractions used in the point-estimate method (a) and in the fixed-margin method (b)
Fig. 4 The number of margins with unreported methods versus
reported methods over time
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between CONSORT-endorsing and non-CONSORT-
endorsing journals. Nevertheless, the extension was pub-
lished in 2006 and was updated in 2010, it may be too
early for the extension to have a significant impact on
reporting non-inferiority trials in general, and on the ra-
tionale for the choice of the margin in particular. Indeed,
the endorsement of the CONSORT Statement has im-
proved the quality of reporting of randomized controlled
trials [24]. For example, the results of a Cochrane review
of 50 evaluation reports of more than 16,000 random-
ized controlled trials showed that the quality of report-
ing clinical trials was better in CONSORT-endorsing
journals [24]. Finally, and in contrast to the results of
the review by Wangge et al. where no difference was
found in reporting the rationale between high- and low-
impact journals [9], the publication in high-impact jour-
nals was associated with better reporting of the methods
used to define the margin.
Among the 115 margins with reported methods, 36.5%
were defined based on expert opinion. This is in line
with the range of margins that were defined by expert
opinions in previous reviews (25 to 75%) [9, 11, 22, 23].
Our findings also highlight the issue of not providing
enough details on the method that was used to define
the margin. Nine margins were chosen because they
were used in similar non-inferiority trials, and five were
defined based on regulatory recommendations or guide-
lines. Moreover, three margins were defined based on lit-
erature reviews without showing the review process or
the type of literature that was reviewed.
Almost 60% of the margins identified in this review
were used without reporting why and how they were se-
lected. This may partially be due unfamiliarity with
methods of defining the margin. This is supported by
the review by Wangge et al. of the regulatory scientific
advice on non-inferiority trials, which showed that 28%
(98 of 354) of the questions and positions about non-
inferiority trials that were sent by the pharmaceutical
companies to the European Medicines Agency (EMA)
were related to the margin [25]. Of the 86 responses to
these questions, the EMA recommended stricter margin
in 35 responses (41%) and questioned the justification of
the margin in another nine (10%) responses. Import-
antly, lack of clarity on how the margins were arrived at
may lead to incorrect decisions made by regulators, health
technology assessment organizations, and health care pro-
fessionals, and ultimately suboptimal health care.
Another contributing factor to the under-reporting of
the rationale is that editors and journals do not strictly
request reporting the exact method that was used to de-
fine the margin. Only two (1.7%) of the 118 journals
state clearly that authors must follow the extension of
the CONSORT Statement for non-inferiority trials if
they are submitting a non-inferiority trial. Editors must
realize that they are accepting non-inferiority trials that
have suboptimal or unclear outcomes because the results
of these trials were analyzed based on unmotivated non-
inferiority margins. Journals should not be accepting
non-inferiority trials without providing the rationale for
the choice of the margin and should put a strong em-
phasis on following the extension of the CONSORT
Statement itself when reporting non-inferiority trials.
In contrast to previous systematic reviews, our system-
atic review provides a detailed description of the
methods being used to define non-inferiority margins,
the impact of the FDA draft guidance on the use of the
fixed-margin method, and the reporting of the rationale
for the choice of the margin in CONSORT-endorsing
and non-CONSORT-endorsing journals. However, our
study has several limitations. First, for 158 of the 273
margins the method to define the margin was not re-
ported. Therefore, we could only use 115 margins to
evaluate for which percentage historical evidence was
used to define the margin. The only predictor of report-
ing the method to define the non-inferiority margin was
the impact factor (high versus low) of the journal in
which the article was published. Under the assumption
of missing data being missing at random (MAR), we also
assessed the percentage of non-inferiority margins that
are based on historical evidence stratified by impact fac-
tor, which were found to be 49% and 36% among high-
and low-impact factor journals, respectively. The contri-
bution of high- and low-impact journals is 58 and 215,
respectively, leading to an estimate of the overall per-
centage of margins that are based on historical evidence
of 39% (accounting for missing data), which does not
materially differ from the 41% mentioned previously.
Second, we might have missed some non-inferiority trials
in our search, because different terms for “non-inferiority”
might have been used or trials may have been published
in journals that are not indexed in PubMed. These might
also be the reasons for not detecting non-inferiority trials
before 2000 in our review. However, in a review that was
conducted to review changes in the publication of non-
inferiority trials over 20 years, only one published non-
inferiority trial was identified between 1989 and 1998 [1].
In that review, the search was conducted in both PubMed
and EMBASE for all randomized non-inferiority trials.
This provides assurance that we have not missed a large
number of trials before 2000. Finally, we have not included
open-label non-inferiority trials in our study, which might
have provided broader evaluation of the methods of defin-
ing non-inferiority margins.
Conclusions
In conclusion, methods of defining non-inferiority mar-
gins are not well reported. Data of those that are re-
ported showed that margins is not commonly defined
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based on the historical evidence of the active comparator
as recommended by regulators, and this, besides the
reporting of the method, has not improved over recent
years. Authors, reviewers, and editors need to take no-
tice of these issues to allow for better judgment of non-
inferiority trials.
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